EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FDG PET/CT Imaging and Circulating Biomarkers of Inflammation in Desmoplakin Cardiomyopathy

Sanjay Divakaran iD, Vinay Randhawa, Usman A Tahir, Matthew Robertson, Anam A Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W Feinberg, Marcelo F Di Carli, Neal K Lakdawala

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Sanjay Divakaran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Cardiomyopathies, Desmoplakins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Brigham and Women's Hospital Heart and Vascular Center Khoury Innovation Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy. We aimed to prospectively investigate if ambulatory patients with DSP cardiomyopathy had myocardial FDG uptake PET/CT imaging indicative of myocardial inflammation and if they had circulating biomarker evidence of inflammation.

Methods

We prospectively recruited participants with DSP cardiomyopathy and participants with titin cardiomyopathy as a comparator group. Blood samples for clinical labs and proteomic profiling, myocardial perfusion single-photon emission computed tomography (SPECT) and myocardial FDG PET/CT were obtained for all participants.

Results

Ten participants with DSP cardiomyopathy (median age 36.5 years (28, 60); 80% female; 100% White and non-Hispanic) and four participants with titin cardiomyopathy (median age 55.5 years [38.5, 64]; 50% female; 100% White and non-Hispanic) were recruited. There were no significant differences between the groups in white blood cell count, ESR, hsCRP or hsTn. Three participants with DSP cardiomyopathy and two participants with titin cardiomyopathy had non-specific myocardial FDG uptake on PET/CT. All other participants had no myocardial FDG uptake. Integration of miRNA differential expression and their predicted targets from the differential expression proteomics data identified a total of 11 inverse miRNA–mRNA pairs potentially involved in the regulation of top 20 significantly enriched pathways, including pathways involved in metabolism, inflammasome/inflammatory signalling and cell death/pyroptosis.

Conclusions

In a group of ambulatory patients with DSP and titin cardiomyopathy, we found no differences in FDG PET/CT findings or clinical circulating biomarkers of inflammation. However, miRNA-seq/proteomics analyses identified several enriched pathways and unique miRNA–protein pairs between DSP and titin cardiomyopathy, including pathways involved in inflammasome/inflammatory signalling. Future work will centre on evaluation during myocarditis-like episodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18CardiomyopathiesDesmoplakinsInflammationHumansFemaleMaleMiddle AgedAdultProspective StudiesBiomarkersRadiopharmaceuticals

Stichwörter der Autor:innen

Arrhythmogenic cardiomyopathyDesmoplakin cardiomyopathyGenetic cardiomyopathyMyocardial inflammation

Substanzen

Fluorodeoxyglucose F18BiomarkersDesmoplakinsRadiopharmaceuticals

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Division of Nuclear Medicine and Molecular Imaging, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • MedStar Health, Washington, DC, USA.

ORCID-Profile: Sanjay Divakaran

Förderung

  • NHLBI NIH HHS
  • Brigham and Women's Hospital Heart and Vascular Center Khoury Innovation Award

Zitieren

APA

Divakaran, S., Randhawa, V., Tahir, U. A., Robertson, M., Waheed, A. A., Perillo, A., Barrett, L., Blankstein, R., Feinberg, M. W., Di Carli, M. F., & Lakdawala, N. K. (2025). FDG PET/CT Imaging and Circulating Biomarkers of Inflammation in Desmoplakin Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15154

Vancouver

Divakaran S, Randhawa V, Tahir UA, Robertson M, Waheed AA, Perillo A, et al. FDG PET/CT Imaging and Circulating Biomarkers of Inflammation in Desmoplakin Cardiomyopathy. ESC Heart Failure. 2025. doi:10.1002/ehf2.15154

BibTeX
@article{Divakaran2025,
  author = {Divakaran, Sanjay and Randhawa, Vinay and Tahir, Usman A and Robertson, Matthew and Waheed, Anam A and Perillo, Anna and Barrett, Leanne and Blankstein, Ron and Feinberg, Mark W and Di Carli, Marcelo F and Lakdawala, Neal K},
  title = {FDG PET/CT Imaging and Circulating Biomarkers of Inflammation in Desmoplakin Cardiomyopathy},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15154}
}
Kostenlos starten →